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ABSTRACT

Corneal wound healing is a complex process involving cell death, migration,
proliferation, differentiation, extracellular matrix remodeling and a various of growth
factors. Of these factors, interleukin-1 and transforming growth factor beta allow the
effectiveness of cell migration and tissue repair. Current management advocates
multiple therapies aimed to prevent inflammation, avoid the fibrosis. Pirfenidone
(PFD) has recently been investigated for its anti-fibrotic effect. The current study was
undertaken to develop and optimize PFD-loaded nanoemulsion (NE; PFD-NE) which
could increase the drug load and the duration of activity. Hot homogenization and
probe sonication methods were used for the preparation of PFD-NEs, sesame oil and
soybean oil as the oil part, Tween 80 and Poloxamer 188 as surfactants.
Physicochemical properties of PFD-NE formulations were characterized such as
particle size, polydispersity index, zeta potential and assay. The physical and chemical
stability of the optimized PFD-NEs were observed under refrigerated and room
temperature for one month. PFD-NE formulations showed desirable physical
properties and observed to be stable for one month. Furthermore, in-vitro release
studies of optimized PFD-NE formulations were performed in comparison with PFD
solution (PFD-C) as control. From the release studies, a sustained release of the PFD
was observed in PFD-NE formulations compared to PFD-C. Generally, the PFD-NE
formulations showed great potential as an alternative delivery system for corneal
wound healing treatment.
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LIST OF ABBREVIATIONS AND SYMBOLS

Pirfenidone: PFD
Nanoemulsion: NE
Polydispersity Index: PDI
Zeta Potential: ZP
High-pressure liquid chromatography: HPLC
Poloxamer 188: P188
Tween®80: T80
Food and drug administration: FDA
Inactive Ingredients Guide: IIG
Percent weight per weight: % w/w
Percent weight per volume: % w/v
Revolutions per minutes: RPM
Millimeter: mm
Microliter: µL
Milliliter: mL
Standard deviation: SD
Nanometer: nm
Percent relative standard deviation: % RSD
Acetonitrile: CAN
Limit of detection: LOD
Limit of quantification: LOQ

iv

Table of Contents
Chapter 1 Introduction ............................................................................................. 1
1.1 Anatomy of the Cornea..................................................................................... 1
1.2 Epithelium wound healing ................................................................................ 1
1.3 The role of GFs and cytokines in epithelial wound healing ............................... 2
1.4 EGF family ...................................................................................................... 3
1.5 TGF-β .............................................................................................................. 3
1.6 Corneal Stromal Wound Healing ...................................................................... 4
1.7 Myofibroblast transdifferentiation in stromal wound healing ............................ 5
Chapter 2 Materials and Methods ............................................................................. 9
2.1 Materials .......................................................................................................... 9
2.2 Methods ........................................................................................................... 9
2.2.1 HPLC method development................................................................................... 9
2.2.2 Screening of Oil...................................................................................................... 10
2.2.3 Surfactant concentration ....................................................................................... 11
2.2.4 Preparation of PFD formulations ........................................................................ 11
2.2.5 Preparation of PFD solution (PFD-C) ............................................................... 12
2.2.6 Characterization of PFD-NE formulations ....................................................... 14
Chapter 3 Results & Discussion ............................................................................. 16
3.1 Effect of oils, surfactants and drug loading ..................................................... 16
3.2 Physical and chemical stability assessment ..................................................... 22
3.3 In-vitro release ............................................................................................... 25
Chapter 4 Conclusion............................................................................................. 28
Reference ................................................................................................................ 29

v

List of Figures
Figure 1 Physical characteristics of various oil concentrations and surfactants ......... 19
Figure 2: Effect of drug loading and surfactant concentration on ............................. 21
Figure 3 Particle size, PDI, ZP and assay of PF-01-NE and PF-02-NE formulations
stored at different conditions within 1 month ........................................................... 24
Figure 4： In-vitro release vs time profiles of PF-01-NE and PF-02-NE formulations
stored at conditions of 4 °C and 25 °C (1month), PFD-C formulation ...................... 27

vi

List of Tables
Table 1 Summary of analytical method of PFD........................................................ 10
Table 2 Composition of placebo NE formulations .................................................... 12
Table 3: Composition of PFD-NE formulations ....................................................... 13
Table 4: Physical characteristics of various oil concentrations and surfactants on NE
placebo formulations at room temperature (mean ± SD, n=3) .................................. 18
Table 5: Effect of drug loading and surfactant concentration on physicochemical
characteristics of PFD-NE formulations (mean ± SD, n=3) ...................................... 20
Table 6: Particle size, PDI, ZP and assay of PF-01-NE and PF-02-NE
formulations stored at conditions of 4 °C and 25 °C (1 month) ................................ 23
Table 7: In vitro release profile of PF-01-NE and PF-02-NE formulations ............... 26
Table 8: Coefficient Relationship (r2) of model fitting for PFD-NE and PFD-C
formulations ............................................................................................................ 26

vii

Chapter 1 Introduction

1.1 Anatomy of the Cornea
Cornea is part of the eye which is exposed to the outside environment and is
therefore most likely to suffer harm due to various threats. Since light enters the eye
first, the cornea provides refractive power which helps to focus light rays on the retina.
Therefore, the cornea is a key component of the refractive ocular system. It is a
translucent and avascular tissue. The human cornea consists of five membranes. It
includes three cellular layers (epithelium, stroma, endothelium) and two interface
layers (Bowman membrane, Descemet membrane). Corneal curvature and
transparency are essential to maintain the corneal refractive force, which accounts for
about 2/3 of the eye's refractive power. The horizontal diameter of the cornea is
11.5-12.0 mm in the average adult and the vertical diameter is smaller by
approximately 1.0 mm.1 Corneal form and curvature are regulated by its intrinsic
biomechanical structure and the extrinsic environment.

1.2 Epithelium wound healing
The epithelium is the outermost layer of the cornea. It is the first barrier to the outside
and is an integral part of the film-corneal interface which is important for the
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refractive ocular system. Corneal epithelium is a self-generating tissue with stem cell
residue in the corneoscleral junction, limbus, and providing proliferating cells for
epithelial regeneration.2 The epithelium wound healing is a dynamic process to
maintain the integrity and protection of the corneal epithelial surface to maintain
corneal consistency and vision. The repairing of corneal epithelial wounds includes
cell migration, proliferation, adhesion and cell layer stratification.3
After injury, at the wound site, an intrinsic cascade involving growth
factor/cytokine and extracellular matrix (ECM) signal-mediated interactions between
epithelial cells, stromal keratocytes, and cells of the immune system control this
process, influencing the expression of matrix metalloproteinases (MMPs). In
physiological conditions, MMPs catalyze ECM molecules, such as collagen,
proteoglycans, and fibronectin, maintaining the structure and functions of the cornea.4
Growth factors (GFs) and cytokines such as interleukin-1 (IL-1) and transforming
growth factor-β (TGF-β), allow the effectiveness of cell migration and tissue repair,
regulate the expression of MMPs. Epithelial cells evoke sequential steps attempting to
re-establish epithelial integrity and restore corneal homeostasis, eventually sealing the
wound.5

1.3 The role of GFs and cytokines in epithelial wound
healing
GFs and cytokines regulate the growth, proliferation, migration, differentiation, ECM
deposition of the cells involved in wound healing. GFs and cytokines play an
important role in mediating different cell functions with intracellular and intercellular
signaling molecules.6 During wound healing, corneal cells express many GFs and
cytokines which have specific effects on epithelial cells, such as epidermal GF (EGF),
2

platelet-derived GF(PDGF) and TGF-α, TGF- β, IL-1, IL-6, IL-10, and tumor
necrosis factor (TNF)-α. Such cellular interactions are not exclusive, and some
activities can base on or mediate other factors.

1.4 EGF family
EGF signaling comprises a major pathway that initiates cell migration and
proliferation and stimulates corneal epithelial wound healing. The EGF family is
composed of up to 13 members and the main members involved in epithelial wound
healing include EGF, TGF-α. The level and function of the EGFR are essential
determinants for the epithelial cell condition in tissues and organs, so maintaining a
sufficient level of EGFR signaling is important for corneal homeostasis. During
wound healing, TGF-α are increased while EGF and mRNA levels remain unchanged,
which indicates EGF maybe indirectly involved in stimulating epithelial wound
closure.3 A few hours after an epithelial injury or corneal inflammation, monocytes,
granulocytes, T-cells and other immune cells migrate to the corneal stroma. When
this occurs, the IL-1 and TNF-α released by epithelial that leading to epithelial cell
migration by activating a variety of responses through ERK, MAP kinases, and/or
NF-κB pathway, then induces the production of monocyte chemotactic stimulant and
granulocyte

colony-stimulant

hormone

through

keratocytes,

attracting

the

inflammatory cells to stroma. 7-9

1.5 TGF-β
The isoforms TGF-β, TGF-β1, TGF-β2 and TGF-β3 are expressed in corneal
epithelium, stromal keratocytes and tear fluids with TGF-β2 expressed at higher
levels.10 TGF-β1 and TGF-β2 inhibit corneal epithelial cell proliferation in vitro while
3

TGF-β3 mediate the binding of other TGF isoforms and further regulate the receptor
activities by the co-receptors endoglin and betaglycan.11 When inactive precursors
attached to latency-associated peptides TGF ligands are either activated or integrated
into the extracellular matrix (ECM) to be activated later. Epithelial wound healing
occurs in a phased process with specific physiological functions. TGF-β stimulates the
migration of corneal epithelial cell via integrin β1, which mediates p38 MAP kinase
activation, ECM expression.12, 13 The p38 MAP kinase delayed the initiation via the
main TGF-β SMAD signaling pathway or by an alternate c-Jun N-terminal kinase
(JNK) pathway.14

1.6 Corneal Stromal Wound Healing
Corneal stromal wounds are common. The response of the corneal wound to
stromal damage requires a sequence of events which would return to normal stromal
structure and function.15 After an epithelial injury, keratocyte death by apoptosis
occurs in the central stroma. The injury-induced keratocyte apoptosis allows
cytokines such as Fas ligand, IL-1, and TNF-α to release out of epithelial cells and/or
tears.16 These cytokines cause rapid apoptosis by Fas/Fas ligand system. More
specifically, IL-1 induces keratocytes to generate Fas ligand RNA and protein to
activate apoptotic autocrine response. Thus, when stimulated by IL-1, both Fas ligand
and Fas are produced, and this simultaneous expression triggers apoptosis via
autocrine mechanisms.17 The stromal apoptosis process typically lasts several days to
a week after the injury. This period also involves the death of inflammatory cells and
other bone marrow-derived cells like myofibroblast precursor cells, which enter the
stream of the limbal vessels immediately. Then, the dying cells in the stroma undergo
necrosis.
4

1.7 Myofibroblast transdifferentiation in stromal wound
healing
Myofibroblasts, sometimes referred to as being ‘activated’ fibroblastic cells, is
considered as a critical factor leading to opacity or fibrosis of the cornea.18 After
corneal epithelial injury, usually 12-24 hours, residual activated keratocytes
proliferate and migrate in the peripheral and posterior stroma change their properties
to become myofibroblast at the wound edges until they completely fill the wound.
Excessive quantities of ECM proteins, including collagen and fibronectin, which
distort normal corneal organization ECM deposit and cross-link,19

cause the

abnormal corneal curvature and refractive error.
In culture, some growth factors (FGF-2 and PDGF-AB, TGF-β) mediate this
process, while others (IL-1 and IGF-1) confer only mitogenic activity.20 The activated
stromal keratocytes (also known as stromal fibroblasts) inhibit the expression of
differentiated keratocyte proteins and begin producing proteinases (usually MMPs)
required to reshape the wound ECM. After entering the wound site, fibroblasts start to
express α-smooth muscle actin (α-SMA) and desmin, upregulate the expression of
vimentin and become highly mobile and contractile myofibroblasts necessary for
wound reconstruction of ECM and wound contraction (Fig 1). These fibroblasts
deposit temporary ECM rich in fibronectin and some other proteins, including
tenascin-C and collagen type III. Myofibroblasts provide contractile forces to close a
wound space, and (α -SMA) expressions directly correlate with the contraction of
corneal wound.21 When wound healing is complete, upregulation of IL-1 produced
by stromal cells triggers the apoptosis of the myofibroblasts and deprives them of
TGF-β.5 Then keratocytes reoccupy the anterior stroma, absorb the abnormal ECM
5

proteins, restore corneal integrity and transparency. During this process, persistent
release of TGF-β leads to the maintenance of the myofibroblasts that continue to
secrete and deposit anomalous ECM, eventually causing corneal haze.
Fibrotic and scarring processes are mainly driven by the proliferation of
fibroblasts and exuberant ECM expression. It was shown that fibroblasts from
different ocular tissues differ in their mRNA profiles.22 Many signaling pathways,
including

the

(PI3K)/AKT

(ERK)/mitogen-activated

pathway,

protein

extracellular

kinase

(MAPK),

signal
c-Jun

regulated

kinase

N-terminal

kinase

(JNK)/MAPK, and p38MAPK pathways, participate in the fibrosis process and
impact fibroblast proliferation.14, 23
Currently, there is no treatment for the eradication of scar tissue, and the
conventional strategy of wound healing modulation is to prevent infections, reduce
inflammation, so as to prevent and avoid the formation of a scar, while ensuring
optimal conjunctival wound healing. One of the wound healing regulations covers all
steps taken against inflammatory cell proliferation and activation. Thus, topical
corticosteroid is an essential part. However, topical ophthalmic corticosteroid use can
result in complications such as intraocular pressure (IOP) elevations, posterior
subcapsular cataract formation with long-term use, secondary infection, and delays in
corneal wound healing.24 Another therapeutic choice is the application of the
antimetabolite mitomycin C (MMC) as a prophylactic after Photorefractive
Keratectomy (PRK) for high myopia. However, due to its antimitotic function,
MMC-induced apoptosis of inactive keratocytes has acute cytotoxicity adverse effects
such as necrosis, and could be related to long-term adverse effects such as corneal
thinning.25 Such difficulties underscore a need to develop effective, safe, and
well-tolerated agents which can modulate the wound healing.
6

PFD (5-methyl-1-phenyl-2-[1H]-pyridone) is a novel compound which shows
anti-fibrotic and anti-inflammatory effects in organs such as the lung 26-29, the liver
27

and the kidney.30 The PFD is a small molecule (molecule weight ≈185g/mol) with

amphiphilic solubility(log D of 1.37 ±0.05).31[need to include what is know about the
physical-chemical properties of the drug including water solubility, Log P, and
stability] In United States, the Food and Drug Administration approved oral PFD for
the treatment of idiopathic pulmonary fibrosis (IPF) in 2014. Recently, several studies
reported the use of PFD in ocular tissues, PFD inhibited human Tenon`s fibroblasts`
(HTFs) proliferation and biological activity in vitro.32 The mechanisms could be act as
by inhibiting mRNA and protein expression of transforming growth factor-β (TGF-β)
isoforms.33 Also, PFD regulates a series of cytokines such as inflammatory cytokines
TNFα and IL-1.34 Additionally, PFD arrested the cell cycle by downregulating
CDK6/cyclin D and CDK2/cyclin E which involved the inhibition of the AKT/GSK3b,
ERK/MAPK, and JNK/MAPK signaling pathways while activated the p38 MAPK
signaling pathway.23 In the eye, PFD has shown the prevention of corneal scarring,
and the inhibition of orbital fibroblasts migration, the anti-fibrotic influence is
primarily due to its antagonism of fibroblast proliferation and migration and the
reduction of matrix deposits of ECM.32 However, when the PFD topically
administered as 0.5% w/v eye drop in rabbit eyes, the pharmacokinetics of PFD
exhibited a shorter half-life in cornea tissue (less than 19 min) as expected for
ophthalmic formulations.35
The topical administration is the most common ophthalmic dosage form as it is
non-invasive, low cost and easy to use. However, poor ocular drug bioavailability is
one of the most difficult areas for researchers to deal with due to the eye's complex
anatomy, physiology and biochemistry.36 Most drugs administered on the ocular
7

surface from solutions are rapidly drained by different mechanisms, such as blinking,
tearing and tear dilution. Tear turnover from lacrimal secretions lead to a majority loss
of the drug. The tear volume of a healthy eye is ~7–9 µL, and its turnover rate is 0.5–
2.2 µL/min.37 The average volume of major formulations during topical
administration is ~35–56 µL, and the excess volume drains into systemic circulation
through the nasolacrimal duct. It is estimated that 5% or even less of the dose
administered enters intraocular devices.38 To improve ocular bioavailability, various
ophthalmic drug delivery systems, emulsions, nanoparticles and suspensions 39-41 have
been proposed. These systems can improve the bioavailability of the drugs facilitating
transcorneal/transconjunctival penetration.
Nanoemulsion (NE) formulations are thermodynamically and kinetically stable
isotropic distributions, composed of multi-component fluids, and usually consist of an
aqueous phase an oil phase, stabilized with a single phase interfacial layer composed
of an primary surfactant as an emulsifying agent, a cosurfactant usually an alkanol of
intermediate chain length and occasionally an electrolyte.42 The major benefits of the
NE formulation involve sustained release of the drug administered to the cornea, high
penetration into the deep layers of the ocular tissue, aqueous humor and ease of
sterilization. Therefore, these processes may have lower dosage and less systemic and
ocular side effects.

8

Chapter 2 Materials and Methods
2.1 Materials
PFD was purchased from Fisher Scientific (TCI America, USA). Castor oil NF grade,
Poloxamer 188, Sesame oil NF grade, Soybean oil NF grade and Tween® 80 (T80)
(polysorbate 80) NF grade were purchased from Spectrum Pharmaceuticals
(Henderson, NV). All other chemicals were purchased from Fisher Scientific (St.
Louis, MO, USA). Solvents used for analysis were of High-Performance Liquid
Chromatography (HPLC) grade.

2.2 Methods
2.2.1 HPLC method development
PFD were analyzed using an HPLC-Ultraviolet system comprising a Waters 717
plus autosampler, Waters 600E pump controller, Waters 2487 dual λ Absorbance
detector. Stock solutions of PFD were prepared in acetonitrile (ACN). A mobile phase
consisting of 80:20 ACN and Millipore water was used on a Phenomenex® C18 (4.6 x
250 mm, 5 microns) column at a flow rate of 1.0 mL/min. The samples were detected
at a wavelength of 314 nm and a runtime of 7 minutes. Each injection volume was 20
µL. The method was validated in accuracy, precision. linearity, LOD and LOQ
according to the guidelines issued by the FDA. The summary of the HPLC method
shown in Table 1.
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Table 1 Summary of HPLC analytical method of PFD
Mobile Phase

80% ACN: 20% Millipore water

Column

Phenomenex Luna® C18 (250x4.6mm,5μm)

Flow rate

1.0 mL/min

Detector

UV

Wavelength

314 nm

Column temperature

Room temperature

Solvent

delivery Waters 600

module
Data processor

Waters 717 plus Auto sampler

Sensitivity

2.0 AUFS

Retention Time

3.5 ± 0.1mins

Linearity (R2)

0.9995

LOD

0.1μg/mL

LOQ

0.25 μg/mL

Precision

% RSD (1.04-2.37)

Accuracy

% RSD (0.12-2.24)

2.2.2 Screening of Oil
Screening of different oils were carried out based on our previous lab work.43 Three
oils were screened based on concentrations disclosed in the Food and Drug
Administration (FDA) Inactive Ingredients Guide (IIG) for ophthalmic or parenteral
use.44 Castor oil is contained in IIG ophthalmic formulations at a concentration of
0.15% w/v. Sesame oil is contained in IIG approved intramuscular emulsion
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formulations at a concentration of 70% w/v. Soybean oil is contained in IIG
intravenous emulsion formulations at a concentration of 20% w/v. NE placebo
formulations were made using the oil concentrations (5% w/v) to determine the
physical characteristics of each formulation.

2.2.3 Surfactant concentration
Surfactants or surfactant and co-surfactant combinations are certain compounds that
are used as emulsifiers at variable concentrations. Based on our lab previous reports,
initial surfactant and co-surfactant concentration screening was undertaken with
various combinations of Poloxamer 188 and Tween 80.43 Poloxamer 188 (0.2% w/v)
and two concentration levels of Tween 80 (0.75 and 2.0% w/v) were chosen to
prepare the NE placebo formulations. In IIG database, Poloxamer 188 is approved up
to 0.2% w/v for intramuscular injection and Tween 80 is up to 4% w/w for ophthalmic
emulsion,

respectively.45

These

formulations

were

evaluated

for

physical

characteristics.

2.2.4 Preparation of PFD-NE formulations
PFD-NE formulations were prepared by homogenization followed by probe
sonication method. The composition of ingredients was listed in Table 2 and Table 3.
PFD was accurately weighed and added to oil to obtain a clear liquid and preheated to
70°C in a water bath. At the same time an aqueous phase comprising Poloxamer 188,
Tween 80, and Glycerin was mixed in double distilled water and heated to 70 °C.
Under continuous mixing, the hot aqueous phase was added to the warm lipid phase
to form a coarse emulsion. At 11,000 rpm, the coarse emulsion was then homogenized
5 minutes at 65 °C (T 25 digital Ultra-Turrax IKA, Germany) to form a fine emulsion.
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The fine emulsion was gradually cooled down to 25 °C before being placed in an ice
bath and ultra-sonic (SONICS® Vibra-Cell™, Newtown, CT, USA) by using a 3mm
stepped microtip probe (40% amplitude; Pulse on: 10 seconds, Pulse off: 15 seconds;
Time: 10 minutes).

2.2.5 Preparation of PFD solution (PFD-C)
PFD control group (PFD-C) was prepared by accurately weighing PFD then adding
PFD and isotonic phosphate buffer saline (IPBS, pH 7.4) in a volume flask to obtain
the 1 mg/mL concentration solution.

Table 2: Composition of placebo NE formulations
Ingredients (% w/v)
Batch
PFD

Castor Oil

Sesame Oil

Soybean Oil

Tween®80

PF-00-NE-P

-

5

-

-

0.75

PF-01-NE-P

-

-

5

-

0.75

PF-02-NE-P

-

-

-

5

0.75

PF-03-NE-P

-

-

5

-

2

PF-04-NE-P

-

-

-

5

2

Each formulation contains 0.2% w/v of poloxamer 188, 2.25% w/v of glycerin and
batch size of 10 mL.
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Table 3: Composition of PFD-NE formulations

Ingredients (% w/v)
Batch
PFD

Castor Oil

Sesame Oil

Soybean Oil

Tween®80

PF-00-NE

-

5

-

-

0.75

PF-01-NE

0.1

-

5

-

0.75

PF-02-NE

0.1

-

-

5

0.75

PF-03-NE

0.1

-

5

-

2

PF-04-NE

0.1

-

-

5

2

PF-05-NE

0.5

-

5

-

0.75

PF-06-NE

0.5

-

-

5

0.75

PF-07-NE

0.5

-

5

-

2

PF-08-NE

0.5

-

-

5

2

Each formulation contains 0.2% w/v of poloxamer 188, 2.25% w/v of glycerin and
batch size of 10 mL.
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2.2.6 Characterization of PFD-NE formulations
Measurement of particle size, polydispersity index (PDI) and zeta Potential (ZP)
The particle size, PDI, and ZP of the placebo and PFD-NE formulations prepared
were determined by using a Zetasizer Nano ZS Zen3600 (Malvern Instruments,
Westborough, MA, USA); a photon correlation spectroscopy device; at 25 °C in a
clear, disposable folded capillary cells. The measurements were attained using a
helium-neon laser based on which the data was analyzed as per the volume
distribution. The samples were diluted 100 times with bi-distilled water prior to
measurements and measured for particle size and zeta potential in triplicate.
Drug content (Assay) of PFD-NE
PFD was extracted from the NE formulations with ACN as extracting solvent. Fifty
microliters of PFD-NE formulation were placed in 5 mL volumetric flasks and the
volume was made up to 5 mL with ACN. The flasks were vortexed and then sonicated
for 15 minutes. The sample was then centrifuged for 10 minutes at 13,300 rpm, in 25℃
(accuSpin Micro 17R, Thermofisher, Germany). The supernatant was further diluted
with ACN and analyzed for PFD content using HPLC.
Physical stability
The stability of selected PFD-NE formulations upon storage was evaluated in closed
glass vials (VWR® Scintillation Vials, Borosilicate Glass, with Screw Caps) at 4°C
and 25°C. The physicochemical characteristics including assay, particle size, PDI, and
ZP were evaluated every week.

In-vitro release study
The in-vitro release study of optimized PFD-NE was evaluated for 6 h by the dialysis
method, using 10kDa Slide-A-Lyzer™ dialysis devices. Prior to the study, cassettes
14

were soaked IPBS (20 mL; pH=7.4) overnight at room temperature. The membrane
cassettes were placed on scintillation vials containing IPBS (20 mL; pH = 7.4) and
maintained in static conditions at 600 rpm under multi-stationed Magnetic Stirrer
(IKA, USA). The temperature was then maintained at 34 ± 1°C throughout the study.
PFD-NE formulations stored after 1 month were used for in-vitro studies. In the
membrane cassettes, 200 µL of PFD-NE and freshly prepared PFD-C were placed in
triplicate. Then 1 mL of aliquot was taken at the chosen interval and fresh IPBS were
added to maintain the persistent volume of the system. The PFD drug release was
analyzed with HPLC as the method mentioned above. The data were analyzed to
determine coefficient (r2) correlation and release kinetics using different mathematical
models.46
a. Zero order model 𝑄 = 𝑄0 + 𝑘𝑡
b. First order model 𝑄 = 𝑄0 ∗ 𝑒 𝑘𝑡
c. Higuchi model 𝑄 = 𝑘 ∗ 𝑡 0.5
d. Korsmeyer–Peppas model 𝑄 = 𝑘 ∗ 𝑡 𝑛
which Q is quantity of drug released in time t, 𝑄0 is the initial value of Q at
zero-time, k is the rate constant, n is the diffusional exponent, a is the time constant
and b is the shape parameter. The correlation coefficient (𝑟 2 ) and the order of release
pattern was calculated in each case.

15

Chapter 3 Results & Discussion
3.1 Effect of oils, surfactants and drug loading on PFD-NE formulation
development
Table 4 displays the physical properties of the NE placebo formulations prepared
with different concentrations of surfactant and oils. The composition of NE placebos
was prepared as described in Table1 but without PFD. The placebos prepared with 5%
w/v of castor oil had higher particle size, which is nearly 1000nm. Smaller particle
size increases the stability of the NE delivery system, avoiding the formation of
aggregates.47 Furthermore, particle size smaller than 200nm can be easily sterilized by
filtration, which is essential for ophthalmic dosage, so it was too large for topical
administration.48 On the other hand, 5% w/v sesame oil and soybean oil, had an
average particle size around 200-300 nm, and ZP was between -20 to -30 mV.
Furthermore, when the Tween 80 concentration increased from 0.75% w/v to 2 % w/v,
particle size was increased. After 7 days, placebos prepared with 5% w/v of sesame
oil and soybean oil with two concentration levels of Tween 80 remained constant in
particle size, PDI and ZP. This resulted in all subsequent experiments using sesame oil
and soybean oil of 5 % w/v and two concentration level of Tween 80 (0.75 and 2%
w/v).
As show in Table 5 initially 0.1%w/v drug load was selected since previous
literature showed PFD had an anti-fibrotic effect in rabbit eye at 5 mg/mL36, with
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Tween 80 concentration at a lower level (0.75% w/v). Then, the drug load was
increased from 0.1% w/v to 0.5 %w/v and the Tween 80 concentration from 0.75%
w/v to 2 % w/v. It was observed that different drug loading did not show significant
change in the particle size, PDI, ZP, and assay. However, when the Tween 80
concentration was 2.0% w/v, the particle size increased. Meanwhile the PDI, ZP, and
Assay did not show significant change in comparison to PFD-NE formulation
prepared with 0.75% w/v Tween 80. The particle size increasing could be attribute to
the aqueous phase remaining the same for all levels, which allowed placebos with a
higher oil concentration to accumulate, resulting in larger particle size. The PDI value
of below 0.5 indicates homogenous, uniformly sized vesicles. The PDI of each
formulation ranged from 0.17-0.24, which demonstrated uniform and homogenous.
ZP value is based on the classical two double layer theory, usually the value between
± 20-30mV demonstrate proper repulsion forces between similar charged particles,
thereby reducing flocculation or aggregation and potentially stabilizes the dispersion.
The ZP results of the PFD-NEs signified that the components of the formulation have
no influence in current experimental conditions. Based on the physiochemical
properties, PF-01-NE and PF-02-NE was selected for further investigation.

17

Table 4: Physical characteristics of various oil concentrations and surfactants on
NE placebo formulations at room temperature (mean ± SD, n=3)

Day 1

Day 7

Batch
Size (nm)

PDI

ZP (mV)

Size (nm)

PDI

ZP (mV)

PF-00-NE-P

988.7±114

0.71±0.16 -24.1±1.9

PF-01-NE-P

222.7±3.0

0.24±0.02 -20.6±0.7

216.0±3.1

0.21±0.04 -22.0±0.1

PF-02-NE-P

222.6±4.2

0.22±0.02 -22.3±0.4

210.3±3.1

0.13±0.00 -24.0±0.6

PF-03-NE-P

293.3±8.9

0.15±0.08 -25.6±0.3

289.8±9.3

0.13±0.07 -27.0±0.6

PF-04-NE-P 278.8±13.9 0.19±0.04 -25.4±0.2

258.6±4.0

0.16±0.05 -24.6±0.3
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Size too large

Figure 1 Physical characteristics of various oil concentrations and surfactants
on NE placebo formulations
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Table 5: Effect of drug loading and surfactant concentration on physicochemical
characteristics of PFD-NE formulations (mean ± SD, n=3)

Formulation

Size (nm)

PDI

ZP (mV)

Assay (%)

PF-01-NE

210.6±4.2

0.24±0.01

-24.5±0.2

95.5±7.1

PF-02-NE

227.2±1.0

0.22±0.01

-22.2±0.3

95.4±0.0

PF-03-NE

276.1±10.7

0.21±0.03

-29.1±0.3

105.0±0.3

PF-04-NE

271.6±3.1

0.24±0.04

-24.7±0.2

115.2±0.2

PF-05-NE

212.9±3.0

0.24±0.01

-20.7±0.2

108.3±0.6

PF-06-NE

225.5±5.1

0.18±0.06

-21.8±0.4

107.6±0.5

PF-07-NE

269.6±5.0

0.17±0.0

-24.7±0.6

96.6±0.4

PF-08-NE

264.8±5.8

0.18±0.0

-26.8±0.3

105.7±0.1
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Figure 2: Effect of drug loading and surfactant concentration on
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3.2 Physical and chemical stability assessment
Stability studies were carried to determine the influence of various excipients on the
drug concentration in PFD-NE and also to determine physicochemical characteristics
of the drug product during storage. The particle size, PDI, ZP and Assay were
observed after one month at 4℃ and 25℃. The PFD-NEs were found to be a
transparent biphasic solution and exhibited no coagulation, aggregation or
precipitation after 1 month. The physical characteristics of PF-01-NE and PF-02-NE
are presented in Table 8. Both PF-01-NE and PF-02-NE did not show a significant
difference on the particle size, PDI, ZP and Assay in different store conditions (4 ℃,
25℃) after 1 month.

22

Table 6: Particle size, PDI, ZP and assay of PF-01-NE and PF-02-NE
formulations stored at conditions of 4 °C and 25 °C (1 month)

Formulation
Stored
condition

Physicochemical
Properties

PF-01-NE

PF-02-NE

Duration (days)

4°C

25°C

Size (nm)

1
203.7±1.0

30
212.4±1.3

1
222.0±3.0

30
225.2±4.5

PDI
ZP (mv)
Assay (%)
Size
PDI

0.25±0.0
-19.2±0.7
102.4±1.4
210.6±4.2
0.24±0.01

0.19±0.0
-27.1±0.9
96.9±2.2
216.0±3.5
0.19±0.01

0.22±0.0
-26.3±0.3
107.4±5.0
227.2±1.0
0.22±0.01

0.16±0.1
-27.8±0.6
97.6±0.4
224.7±5.1
0.16±0.01

ZP
Assay (%)

-24.5±0.2
95.5±7.1

-23.5±0.3
97.8±1.4

-22.2±0.3
95.4±0.0

-20.9±1.1
99.3±0.4
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Figure 3 Particle size, PDI, ZP and assay of PF-01-NE and PF-02-NE
formulations stored at different conditions within 1 month
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3.3 In-vitro release
The in-vitro release studies were designed to mimic the in-vivo behavior of the
formulations. In the present work, to mimic tear fluid, in-vitro release experiments
were performed at pH 7.4. The release percentage of PFD at periodic time intervals
from PF-01-NE and PF-02-NE after 1 month in comparison with PFD-C formulation
shown is in Table 7 and Figure 4. The PFD-C formulation was observed to have a
complete release within 4 h while PFD-NE formulations showed complete drug
release within 6 h, indicating a sustained release profile compared with PFD-C
formulation. The release mechanism for each formulation was studied by various
models and the results are summarized in Table 8. The modeling results demonstrate
that the kinetics of PFD-NE formulations better fit the Korsmeyer-Peppas model
while PFD-C formulation better fit the First order model (r2=0.993). Drug release
following the Korsemeyer-Peppas model means a number of synchronized steps
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usually occur that are expected for modified dosage form including diffusion of water
and the coupling of the active ingredient diffusion and the oil.

Table 7: In vitro release profile of PF-01-NE and PF-02-NE formulations
stored at conditions of 4 °C and 25 °C (1month), PFD-C formulation
(mean ± SD, n = 3)
Drug release (%)
Stored at 4℃

Time (h)

Stored at 25℃

PFD-C

PF-01-NE

PF-02-NE

PF-01-NE

PF-02-NE

0.5

39.5±1.7

29.4±2.6

29.8±0.9

29.7±1.5

30.6±0.7

1

57.2±1.7

40.7±3.0

39.9±1.5

40.2±0.8

42.3±2.7

2

76.2±1.1

56.5±2.6

56.1±0.9

57.4±1.9

57.7±3.6

4

86.3±1.3

73.3±2.1

73.5±1.6

72.4±2.4

76.5±2.1

6

84.1±1.0

78.5±1.8

80.2±2.7

78.4±2.7

81.6±1.4

Table 8: Coefficient Relationship (r2) of model fitting for PFD-NE and PFD-C formulations
PF-01-NE
Model Name

PF-02-NE

PF-01-NE

PF-02-NE

PFD-C
Stored at 4℃

Stored at 25℃

Zero order

0.7016

0.9008

0.8938

0.8989

0.9067

First order

0.9932

0.9748

0.9679

0.9752

0.9710

Higuchi

0.8259

0.9696

0.9797

0.9684

0.9723

Korsmeyer-Peppas

0.8781

0.9804

0.9872

0.9797

0.9820
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Figure 4： In-vitro release vs time profiles of PF-01-NE and PF-02-NE
formulations stored at conditions of 4 °C and 25 °C (1month), PFD-C formulation
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Chapter 4 Conclusion
The NE formulation of PFD were successfully formulated and optimized using
soybean oil and sesame oil as oil components, Tween 80 and poloxamer 188 as
surfactants. and glycerin as co surfactants, respectively. Optimized NE formulation
showed desirable physical characteristics with 100 ± 5% drug content (Assay%).
Selected PFD-NE formulations were stable at 4 ℃ and 25 ℃ for one month. The in
vitro release study revealed the sustain release of PFD in the NE formulation,
compared to PFD solution used a control formulation. Further studies include
optimize the stability of the formulations for a longer duration of time and in-vitro
transcorneal study to confirm the permeability of the formulation.
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